See the DrugPatentWatch profile for keytruda

At this point, there is no definitive answer as to when Keytruda generics will be released. Keytruda, a medication used to treat various forms of cancer, is currently under patent protection. The drug's manufacturer, Merck & Co., holds the exclusive rights to produce and sell Keytruda in the United States until the patents expire [1].

According to DrugPatentWatch.com, Keytruda's primary patent is set to expire in October 2028 [1]. However, it is important to note that the release of generic versions of a drug does not automatically occur once the patent expires. The Food and Drug Administration (FDA) must approve the generic drug before it can be marketed and sold [2].

Moreover, there may be additional patents protecting Keytruda beyond the primary patent, such as secondary patents on formulations, methods of use, or manufacturing processes [1]. These secondary patents can potentially delay the entry of generic competitors into the market.

In summary, Keytruda generics are expected to be released after the primary patent expires in October 2028, assuming there are no secondary patents delaying the release. However, the actual release date may vary depending on the FDA's approval process and any potential legal challenges from Merck & Co.

Sources:
[1] DrugPatentWatch.com, "Keytruda (pembrolizumab) - Patent Expiration & Drug Sales", https://www.drugpatentwatch.com/patent/keytruda-pembrolizumab-us-patent-expiration-and-sales-data/
[2] U.S. Food and Drug Administration, "Generic Drugs: Questions and Answers", https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/generic-drugs-questions-and-answers